论文部分内容阅读
为做好应对人感染H7N9禽流感疫情的科技支撑工作,“重大新药创制”科技重大专项于2013年4月组织神州细胞工程有限公司等单位实施了人感染H7N9禽流感应急抗体制备和研发项目。目前,该项目进展顺利,已完成人感染H7N9禽流感人源化中和抗体的临床前研究并申报临床试验。为加快推进该项目实施进程,2014年2月12日,新药专项行政责任人、国家卫生和计划生育委员会副主任刘谦同志主持召开“人感染H7N9禽流感人源化中和抗体论证会”。会议听取了项目研发进展情况汇报并进行了充分讨论。与会专家
In order to do a good job in scientific and technological support for the human infection of H7N9 bird flu, major scientific and technological projects such as “Major New Drugs Creation” were organized in April 2013 to carry out the preparation and research and development of human antibody against H7N9 avian influenza project. At present, the project is progressing well and has completed the preclinical study on humanized neutralizing antibodies to human H7N9 bird flu and declared clinical trials. In order to speed up the project implementation process, on February 12, 2014, Comrade Liu Qian, deputy director of the New Drug Administration and the deputy director of the State Health and Family Planning Commission, convened the “Human Infection-neutralization Antibody Demonstration Conference on H7N9 Avian Influenza” . The meeting listened to the report on the progress of the project research and carried out a full discussion. Participating experts